Morning Briefing
Summaries of health policy coverage from major news organizations
How Theranos' Fall From Grace Killed Walgreens' Infatuation With The Startup
In 2013, Walgreens hoped to bask in the glow of the blood-testing company that was one of Silicon Valley's hottest unicorns. Now, as Theranos faces multiple investigations into its practices and technology, the chain is trying to distance itself as much as possible from its once-touted partner.
Many boldface names enabled the stratospheric rise of the blood-testing start-up Theranos: two former secretaries of state, a former secretary of defense, two former senators, a retired admiral, venture capitalists, scientific luminaries and a prestigious clinic. None has been more important to Theranos than Walgreens. (Stewart, 4/21)
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
